Close

Apricus Biosciences (APRI) Reports Completion of Transfer of Vitaros German Marketing Authorization

Go back to Apricus Biosciences (APRI) Reports Completion of Transfer of Vitaros German Marketing Authorization

Apricus Biosciences Announces Completion of Transfer of VitarosĀ® German Marketing Authorization to Ferring Pharmaceuticals

August 10, 2016 7:00 AM EDT

SAN DIEGO, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Ferring Pharmaceuticals, the Companys new partner in Germany, has received the German marketing authorization for Vitaros®.

We are pleased that the transfer of the German marketing authorization to Ferring, a critical step in Ferrings plan to re-launch Vitaros in this important market, has been completed, said Richard Pascoe, Chief Executive Officer of Apricus. Moreover, this marks the first in a series of marketing authorization... More